Lincomycin microbiology

Lincomycin

LINCOCIN®, LINCOMED®, LINCOMIX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Compatiblity
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Abdurahman Khalil, M.D. [2]

## Microbiology

[edit | edit source]

Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (seeINDICATIONS AND USAGE).

Staphylococcus aureus (penicillinase- and non-penicillinase producing strains) Streptococcus pneumoniae

The following in vitro data are available; but their clinical significance is unknown.

Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials.

Aerobic gram-positive cocci: Streptococcus pyogenes  Viridans group streptococci

Aerobic gram-positive bacilli: Corynebacterium diphtheriae

Anaerobic gram-positive non-sporeforming bacilli: Propionibacterium acnes

Anaerobic gram-positive sporeforming bacilli: Clostridium tetani Clostridium perfringens

This drug is not active against most strains of Enterococcus faecalis nor against Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae or other gram-negative organisms or yeasts.

Cross resistance has been demonstrated between clindamycin and lincomycin. Some cross resistance witherythromycin including a phenomenon known as dissociated cross resistance ormacrolide effect has been reported.

Studies indicate that lincomycin does not share antigenicity with penicillin compounds.

## References

[edit | edit source]

http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050317s172lbl.pdf